About: Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
Creator	Buonavoglia, Canio Decaro, Nicola Elia, Gabriella Mari, Viviana Martella, Vito Colao, Valeriana Losurdo, Michele Catella, Cristiana Sciarretta, Rossana Giudice, Giuseppe
source	Elsevier; Medline; PMC
abstract	Abstract Recently, canine coronavirus (CCoV) strains with putative recombinant origin with porcine transmissible gastroenteritis virus (TGEV) were shown to be widespread in Europe. In this study, a killed vaccine against TGEV-like CCoV strains, included in the new subtype CCoV-IIb, was developed through inactivation with betapropiolactone and emulsification with MF59™ adjuvant. Safety, immunogenicity and efficacy of the developed vaccine were evaluated in vivo. Five 10-week-old beagle pups were administered (three weeks apart) two vaccine doses, whereas two animals served as unvaccinated controls. The vaccine was shown to be safe as no local neither systemic reactions were observed after first and second dose administration. Serum antibodies against CCoV were detected in vaccinates starting from study day 14 (by enzyme-linked immunosorbent assay) or 28 (by virus neutralisation test). Subsequent challenge with virulent CCoV-IIb resulted in the development of mild gastroenteric disease in control pups, whereas vaccinates did not display clinical signs. Faecal shedding of the challenge virus occurred in both treatment groups, but vaccinated dogs were found to shed very low viral titres in comparison to controls. The developed vaccine may help control the CCoV-IIb-induced disease (and active virus circulation) in environments, such as kennels and shelters, where the pathogenic potential of this virus is greater as a consequence of predisposing factors and concurrent infections.
has issue date	2011-03-03(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2011.01.028
bibo:pmid	21272607
has license	els-covid
sha1sum (hex)	d1d6cfcd65bfc9b918ef9ad6fdc7d3702d755ccb
schema:url	https://doi.org/10.1016/j.vaccine.2011.01.028
resource representing a document's title	Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
has PubMed Central identifier	PMC7115603
has PubMed identifier	21272607
schema:publication	Vaccine
resource representing a document's body	covid:d1d6cfcd65bfc9b918ef9ad6fdc7d3702d755ccb#body_text
is schema:about of	named entity 'killed' named entity 'mild' named entity 'virus' named entity 'disease' covid:arg/d1d6cfcd65bfc9b918ef9ad6fdc7d3702d755ccb named entity 'circulation' named entity 'doses' named entity 'dose' named entity 'emulsification' named entity 'developed' named entity 'weeks' named entity 'porcine' named entity 'recombinant' named entity 'TGEV' named entity 'Serum' named entity 'porcine' named entity 'adjuvant' named entity 'vaccine' named entity 'canine coronavirus' named entity 'Faecal' named entity 'virus' named entity 'vaccine' named entity 'adjuvanted' named entity 'coronavirus' named entity 'vaccine' named entity 'disease' named entity 'genome' named entity 'vaccination' named entity 'TGEV' named entity 'MF59' named entity 'Italy' named entity '21 days' named entity 'dog food' named entity 'immunogenicity' named entity 'virus' named entity 'virulent' named entity 'viral species' named entity 'canine distemper virus' named entity 'serum samples' named entity 'gastroenteritis' named entity 'reoviruses' named entity 'Milan' named entity 'nostril' named entity 'clinical signs' named entity 'gastroenteritis' named entity 'porcine' named entity 'Italian Ministry of Health' named entity 'convulsion' named entity 'vaccine' named entity 'MF59' named entity 'virus' named entity 'infection' named entity 'vaccine' named entity 'antigen' named entity 'MF59' named entity 'systemic reactions' named entity 'cytopathic effect' named entity 'systemic reactions' named entity 'virus' named entity 'Viral' named entity 'Vaccine' named entity 'Canine' named entity 'monoclonal antibody' named entity 'Italian' named entity 'treatment group' named entity 'vaccine' named entity 'Vaccine' named entity 'mixed infections' named entity '8 days' named entity 'vaccine' named entity 'FCoV' named entity 'hypervirulent'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software